Moderna, Inc. Hits New 52-Week High at $69.90, Signaling Recovery

Moderna, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 69.90 on June 29, 2026. This achievement marks a notable rebound from its 52-week low of USD 22.29, showcasing a substantial increase in its stock price over the past year. Despite this recent uptick, Moderna's one-year performance reflects a decline of 53.09%, contrasting sharply with the S&P 500's gain of 20.53% during the same period. The company's market capitalization stands at approximately USD 19,573 million, indicating its mid-cap status within the industry. Financial metrics reveal that Moderna is currently loss-making, with a negative return on equity of -32.62% and a debt-to-equity ratio of -0.60. The company does not offer a dividend, and its price-to-book ratio is 2.26. As Moderna continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent high may signal a pivotal moment in its market journey.